Volume 5 Issue 6
Nov.  2014
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2014  >  5(6): 368-373
Zhou Lin, Suo Longlong, Song Jiyong, et al. Influence of sirolimus based triple anti-tumor therapy on T lymphocyte of rat model with liver cancer recurrence after transplantation[J]. ORGAN TRANSPLANTATION, 2014, 5(6): 368-373. doi: 10.3969/j.issn.1674-7445.2014.06.009
Citation: Zhou Lin, Suo Longlong, Song Jiyong, et al. Influence of sirolimus based triple anti-tumor therapy on T lymphocyte of rat model with liver cancer recurrence after transplantation[J]. ORGAN TRANSPLANTATION, 2014, 5(6): 368-373. doi: 10.3969/j.issn.1674-7445.2014.06.009
shu

Influence of sirolimus based triple anti-tumor therapy on T lymphocyte of rat model with liver cancer recurrence after transplantation

doi: 10.3969/j.issn.1674-7445.2014.06.009
  • 1.

    Department of Hepatobiliary Surgery, Organ Transplantation Institute of People's Liberation Army, the 309 Hospital of People's Liberation Army, Beijing 100091, China

More Information
  • Corresponding author: Du Guosheng, Email:duguosheng@medmail.com.cn
  • Received Date: 2014-08-01
    Available Online: 2021-01-19
  • Publish Date: 2014-11-15
    Abstract
  •   Objective   To explore the influence of triple anti-tumor therapy which bases on sirolimus combined huaier granule and thymosin α-1 on T lymphocyte of rat model with liver cancer recurrence after transplantation.   Methods   Seventy-two Sprague-Dawley(SD)rats were randomly divided into triple therapy group, sirolimus group, huaier-granule group, thymosin α-1 group, positive-control group and blank group(n=12 in each group). Except the blank group, rats in all the other groups were established the simulation animal model of liver cancer recurrence after liver transplantation by chemical-induced method. After the model was established, rats in the positive control group were executed to appraise whether the model was successful. The proportion of regulatory T cells (Treg) of CD4+ T lymphocytes in peripheral blood (Treg%), the percentage of CD4+ T lymphocyte of total lymphocyte(CD4+T%)and the percentage of CD8+ T lymphocyte of total lymphocyte (CD8+T%), were detected by the flow cytometry respectively. The relationship between Treg% and CD4+ T%, CD8+ T%, the ratio of CD4+/CD8+ T lymphocytes(CD4+/CD8+)was analyzed by the method of Spearman rank correlation.   Results   Pathological section of rat liver tissue suggested that the rat model was established successfully. Treg% of positive control group was higher than that of blank group, the difference had statistical significance(P<0.05). Treg% of triple therapy group was significantly lower than that of the positive control group, huaier-granule group, thymosin α-1 group, and significantly higher than the blank group(all in P<0.05). Compared with positive-control group, CD4+T% and CD8+T% of triple therapy group, sirolimus group and thymosin α-1 group were significantly higher (all in P<0.05). CD4+T% and CD8+T% of triple therapy group were significantly higher than those of thymosin α-1 group, sirolimus group and huaier-granule group (all in P<0.05). The relationship between Treg% and CD4+T%, CD8+T%, CD4+/CD8+ in peripheral blood were negatively correlated for rats in each group. In addition, the triple anti-tumor therapy decreased the negative correlation between Treg% and CD4+/CD8+.   Conclusions   Sirolimus based triple anti-tumor therapy can decrease the peripheral blood Treg level of the liver cancer rat, increase the number of T lymphocyte and CD4+/CD8+, and play the role of anti tumor cell growth and proliferation.

     

    • FullText(HTML)
  • loading
    • References(23)
  • [1]
    Venook AP, Papandreou C, Furuse J, et al. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective[J]. Oncologist, 2010, 15(Suppl 4):5-13. http://cn.bing.com/academic/profile?id=2145595073&encoded=0&v=paper_preview&mkt=zh-cn
    [2]
    Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2012, 379(9822):1245-1255. doi: 10.1016/S0140-6736(11)61347-0
    [3]
    Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2):69-90. doi: 10.3322/caac.v61:2
    [4]
    Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma[J]. Semin Liver Dis, 2005, 25(2):181-200. doi: 10.1055/s-2005-871198
    [5]
    Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma:an update[J]. Hepatology, 2011, 53(3):1020-1022. doi: 10.1002/hep.24199
    [6]
    Davis E, Wiesner R, Valdecasas J, et al. Treatment of recurrent hepatocellular carcinoma after liver transplantation[J]. Liver Transpl, 2011, 17(Suppl 2):S162-S166. http://cn.bing.com/academic/profile?id=2077626674&encoded=0&v=paper_preview&mkt=zh-cn
    [7]
    Park MS, Lee KW, Suh SW, et al. Living-donor liver transplantation associated with higher incidence of hepatocellular carcinoma recurrence than deceased-donor liver transplantation[J]. Transplantation, 2014, 97(1):71-77. doi: 10.1097/TP.0b013e3182a68953
    [8]
    Sharma P, Welch K, Hussain H, et al. Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era[J]. Dig Dis Sci, 2012, 57(3):806-812. doi: 10.1007/s10620-011-1910-9
    [9]
    Welker MW, Bechstein WO, Zeuzem S, et al. Recurrent hepatocellular carcinoma after liver transplantation: an emerging clinical challenge[J]. Transpl Int, 2013, 26(2):109-118. doi: 10.1111/tri.2013.26.issue-2
    [10]
    Matter MS, Decaens T, Andersen JB, et al. Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends[J]. J Hepatol, 2014, 60(4):855-865. doi: 10.1016/j.jhep.2013.11.031
    [11]
    Cholongitas E, Mamou C, Rodríguez-Castro KI, et al. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review[J]. Transpl Int, 2014, 27(10):1039-1049. doi: 10.1111/tri.2014.27.issue-10
    [12]
    Liang W, Wang D, Ling X, et al. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis[J]. Liver Transpl, 2012, 18(1):62-69. doi: 10.1002/lt.v18.1
    [13]
    杜国盛, 周林, 石炳毅, 等. 三联抗肿瘤疗法预防晚期原发性肝癌肝移植术后肿瘤复发的临床研究[J].器官移植, 2014, 5(2):74-78. http://www.cnki.com.cn/Article/CJFDTOTAL-QGYZ201402006.htm

    Du GS, Zhou L, Shi BY, et al. Clinical study of triple anti-tumor therapy for preventing tumor recurrence of terminal primary liver cancer after liver transplantation[J]. Organ Transplant, 2014, 5(2):74-78. http://www.cnki.com.cn/Article/CJFDTOTAL-QGYZ201402006.htm
    [14]
    周林, 杜国盛, 朱志东, 等. 预防晚期肝内胆管细胞癌肝移植术后复发的三联疗法疗效报道[J/CD]. 中华普外科手术学杂志: 电子版, 2014, 8(1): 40-43.

    Zhou L, Du GS, Zhu ZD, et al. Prevention of recurrence of end-stage intrahepatic cholangiocellular carcinoma after liver transplantation by triple therapy[J/CD]. Chin J Oper Proc Gen Surg: Electronic Edition, 2014, 8(1): 40-43.
    [15]
    Thakur S, Singla A, Chawla Y, et al. Expansion of peripheral and intratumoral regulatory T cells in hepatocellular carcinoma: a case-control study[J]. Indian J Pathol Microbiol, 2011, 54(3):448-453. doi: 10.4103/0377-4929.85073
    [16]
    Mathai AM, Kapadia MJ, Alexander J, et al. Role of Foxp3-positive tumor-infiltrating lymphocytes in the histologic features and clinical outcomes of hepatocellular carcinoma[J]. Am J Surg Pathol, 2012, 36(7):980-986. doi: 10.1097/PAS.0b013e31824e9b7c
    [17]
    陈颖华, 蔡常洁, 陆敏强, 等.建立符合肝癌肝移植术后肝癌复发规律的大鼠模型[J].中山大学学报:医学科学版, 2006, 27(6):640-643. http://www.cnki.com.cn/Article/CJFDTOTAL-ZSYK200606013.htm

    Chen YH, Cai CJ, Lu MQ, et al. A new rat model according with recrudescent mechanism after liver transplantation[J]. J Sun Yat-sen Univ: Medical Science, 2006, 27(6):640-643. http://www.cnki.com.cn/Article/CJFDTOTAL-ZSYK200606013.htm
    [18]
    Du Y, Chen X, Huang ZM, et al. Increased frequency of Foxp3+ regulatory T cells in mice with hepatocellular carcinoma[J]. Asian Pac J Cancer Prev, 2012, 13(8):3815-3819. doi: 10.7314/APJCP.2012.13.8.3815
    [19]
    Lin SZ, Chen KJ, Xu ZY, et al. Prediction of recurrence and survival in hepatocellular carcinoma based on two Cox models mainly determined by FoxP3+ regulatory T cells[J]. Cancer Prev Res, 2013, 6(6):594-602. doi: 10.1158/1940-6207.CAPR-12-0379
    [20]
    Sakaguchi S, Sakaguchi N, Asano M, et al. Pillars article: immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995[J]. J Immunol, 2011, 186(7):3808-3821.
    [21]
    Chen X, Du Y, Huang Z. CD4+ CD25+ Treg derived from hepatocellular carcinoma mice inhibits tumor immunity[J]. Immunol Lett, 2012, 148(1):83-89. doi: 10.1016/j.imlet.2012.09.002
    [22]
    Lee WC, Wu TJ, Chou HS, et al. The impact of CD4+ CD25+ T cells in the tumor micro environment of hepatocellular carcinoma[J]. Surgery, 2012, 151(2):213-222. doi: 10.1016/j.surg.2011.07.029
    [23]
    Huang Y, Liao H, Zhang Y, et al. Prognostic value of tumor-infiltrating FoxP3+ T cells in gastrointestinal cancers: a meta analysis[J]. PLoS One, 2014, 9(5):e94376. doi: 10.1371/journal.pone.0094376
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (128) PDF downloads(5) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return